Medication Self-Management Technology for Older Adults

NCT07754994 | Not Yet Recruiting

• 1 other identifier: 26-0336
• Study Type: interventional
• Target: 40
• Locations: 0 countries
• Sites: N/A

Brief Summary

The goal of this feasibility study is to evaluate the preliminary impact of a mobile health application (app) called bpMedManage-R, designed to support hypertension medication self-management in persons with mild cognitive impairment (PwMCI) who live alone. The main questions this study aims to answer are whether the bpMedManage-R app shows preliminary impact on medication-related self-regulation (the ability to consistently take medications as prescribed) and self-efficacy (confidence in independently managing medication use). Participants will be randomized after a baseline assessment to the bpMedManage-R Immediate Group or the bpMedManage-R Delayed Group. Participants assigned to the Immediate Group will complete a 4-week baseline adherence period, at the end of which they will enter the intervention phase. A remote training session will be conducted to initiate the intervention phase, during which participants will download the app, learn to use it, and set up their medication schedule and reminders within the app with support from the study team. They will then use the app for 8 weeks to self-manage their medications, take part in brief weekly check-ins to review progress, and complete Outcome Assessment 1 at the end of the 8-week intervention phase. Participants assigned to the Delayed Group will complete a 12-week baseline adherence period, at the end of which they will complete Outcome Assessment 1. Subsequently, they will enter the intervention phase and will follow a process similar to that of the Immediate Group. At the end of the 8-week intervention phase, they will complete Outcome Assessment 2. Researchers will compare participants who receive the bpMedManage-R app intervention immediately to those assigned to the delayed control group.

Conditions

Mild Cognitive Impairment (MCI)

Outcome Measures

Primary Outcomes (3)

• Change in Self-regulation Measured by Adapted Short Self-Regulation Questionnaire (SSRQ)

  A 31-item measure of the ability to regulate behavior in order to achieve desired future outcomes.

  Immediate Group: Baseline; 8 weeks post-intervention Delayed Group: Baseline; 8 weeks post wait-list period; 8 weeks post-intervention

• Change in Medication Usage Self-efficacy Measured by Medication Usage Self-Efficacy (MUSE) questionnaire

  A brief 8-item tool that measures how confident a person is in understanding and taking their prescribed medications.

  Immediate Group: Baseline; 8 weeks post-intervention Delayed Group: Baseline; 8 weeks post wait-list period; 8 weeks post-intervention

• Change in Medication Usage Self-efficacy Measured by Medication Adherence Self-Efficacy Scale-revised (MASES-R)

  A13-item questionnaire that measures a person's confidence in taking their medication even when faced with difficult situations.

  Immediate Group: Baseline; 8 weeks post-intervention Delayed Group: Baseline; 8 weeks post wait-list period; 8 weeks post-intervention

Study Arms (2)

bpMedManage R Immediate Group

EXPERIMENTAL

Participants will first complete a 4 week baseline medication adherence monitoring period followed by 8 weeks of intervention.

Other: Immediate Intervention Arm

bpMedManage R Delayed Group

OTHER

Participants will first complete a 12 week of baseline medication adherence monitoring period followed by 8 week of intervention.

Other: Delayed Intervention Arm

Interventions

Immediate Intervention Arm OTHER

Participants will first complete a 4 week baseline medication adherence monitoring period. After this period, they will attend a video conferencing session with the research team to receive guidance on downloading and using the bpMedManage R app. They will also set personalized goals for self-monitoring their medication daily and weekly using the app. Participants will then use the app for 8 weeks to monitor their medication adherence along with brief weekly check ins to address questions or technical issues. At the end of the 8 week intervention, participants will complete a final assessment.

bpMedManage R Immediate Group

Delayed Intervention Arm OTHER

Participants will first complete a 12 week baseline medication adherence monitoring period. At the end of this period, they will attend a video conferencing session with the research team during which they will complete a brief assessment and receive guidance on downloading and using the bpMedManage R app. They will also set personalized goals for self-monitoring their medication daily and weekly using the app. Participants will then use the app for 8 weeks, along with brief weekly check ins to address questions or technical issues. At the end of the 8 week intervention, they will complete a final assessment.

bpMedManage R Delayed Group

Eligibility Criteria

• Age: 60 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age 60+
• Fluent in English
• Adequate visual and auditory acuity
• Community dwelling
• Lives alone
• Self-reported memory problems
• Manage at least one hypertension medication
• Passing score on Telephone Interview for Cognitive Status - Modified (TICS- M) between 27-37
• Passing score on Montreal Cognitive Assessment (MoCA) between 20 and 26
• Geriatric Depression Scale (GDS) score of 6 or lower
• Stated willingness to comply with all study procedures and availability for the duration of the study

You may not qualify if:

• Diagnosis of dementia
• Major communication difficulties

Sponsors & Collaborators

• University of Illinois at Urbana-Champaign: lead
• Arizona State University: collaborator

MeSH Terms

Conditions

Cognitive Dysfunction

Condition Hierarchy (Ancestors)

Cognition Disorders; Neurocognitive Disorders; Mental Disorders

Central Study Contacts

Raksha Mudar

CONTACT

217-333-4718; raksha@illinois.edu

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 9, 2026
• First Posted: August 10, 2026
• Study Start (Estimated): October 1, 2026
• Primary Completion (Estimated): December 1, 2027
• Study Completion (Estimated): June 1, 2028
• Last Updated: August 10, 2026

Record last verified: 2026-06